Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Expected to Announce Earnings of -$0.51 Per Share

Wall Street analysts expect that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will report ($0.51) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.52). Zynerba Pharmaceuticals reported earnings of ($0.44) per share in the same quarter last year, which would indicate a negative year over year growth rate of 15.9%. The firm is scheduled to issue its next earnings results on Monday, March 9th.

On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($1.65) per share for the current fiscal year, with EPS estimates ranging from ($1.98) to ($1.47). For the next fiscal year, analysts expect that the business will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.57). Zacks’ EPS averages are an average based on a survey of analysts that follow Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.08.

A number of analysts recently issued reports on ZYNE shares. Jefferies Financial Group reissued a “hold” rating and set a $11.00 price objective on shares of Zynerba Pharmaceuticals in a research report on Monday, September 16th. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. ValuEngine raised shares of Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday. Needham & Company LLC began coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, October 21st. They set a “buy” rating and a $18.00 target price for the company. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and set a $26.00 price target on shares of Zynerba Pharmaceuticals in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Zynerba Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $19.71.

Shares of Zynerba Pharmaceuticals stock traded up $0.08 during trading hours on Wednesday, hitting $5.71. The company’s stock had a trading volume of 267,547 shares, compared to its average volume of 1,428,174. The stock has a market cap of $130.60 million, a price-to-earnings ratio of -2.19 and a beta of 4.62. Zynerba Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $16.47. The firm has a fifty day moving average of $6.82 and a 200-day moving average of $10.11.

A number of large investors have recently added to or reduced their stakes in the business. ETF Managers Group LLC purchased a new stake in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at $30,323,000. BlackRock Inc. lifted its position in shares of Zynerba Pharmaceuticals by 341.4% during the second quarter. BlackRock Inc. now owns 1,311,995 shares of the company’s stock worth $17,778,000 after purchasing an additional 1,014,749 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Zynerba Pharmaceuticals by 127.8% during the second quarter. Vanguard Group Inc. now owns 1,232,456 shares of the company’s stock worth $16,700,000 after purchasing an additional 691,342 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth about $1,865,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Zynerba Pharmaceuticals in the second quarter valued at approximately $789,000. Institutional investors own 45.31% of the company’s stock.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

Featured Story: Market Capitalization

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.